Loviride is an experimental antiviral drug manufactured by Janssen (now part of Janssen-Cilag) that is active against HIV. Loviride is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that entered phase III clinical trials in the late 1990s, but failed to gain marketing approval because of poor potency.[1] It is of clinical significance only in those patients who were enrolled in clinical trials to evaluate loviride (e.g., CAESAR[2] and AVANTI[3]), because in those trials loviride was often given alone and with no companion drug, leading to a high probability of developing reverse transcriptase mutations such as K103N which result in cross-class resistance to the NNRTIs efavirenz and nevirapine.

References

  1. ^ "Loviride". aidsmap.com. Archived from the original on 2007-09-27.
  2. ^ Kroon ED, Wit FW, et al. (CAESAR Coordinating Committee) (1997). "Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial". The Lancet. 349 (9063): 1413–1421. doi:10.1016/S0140-6736(97)04441-3. S2CID 20008082.
  3. ^ Gatell J, Lange J, Gartland M (1999). "AVANTI 1: randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus loviride in HIV-infected antiretroviral-naive patients. AVANTI Study Group". Antiviral Therapy. 4 (2): 79–86. doi:10.1177/135965359900400204. PMID 10682152. S2CID 22443598.
Allikas: https://en.wikipedia.org/wiki/Loviride
No tags for this post.